JP2020501589A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020501589A5 JP2020501589A5 JP2019534134A JP2019534134A JP2020501589A5 JP 2020501589 A5 JP2020501589 A5 JP 2020501589A5 JP 2019534134 A JP2019534134 A JP 2019534134A JP 2019534134 A JP2019534134 A JP 2019534134A JP 2020501589 A5 JP2020501589 A5 JP 2020501589A5
- Authority
- JP
- Japan
- Prior art keywords
- herpes simplex
- simplex virus
- oncolytic herpes
- subject
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 34
- 230000000174 oncolytic effect Effects 0.000 claims description 33
- 241000700584 Simplexvirus Species 0.000 claims description 29
- 206010028980 Neoplasm Diseases 0.000 claims description 27
- 230000002503 metabolic effect Effects 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 230000002601 intratumoral effect Effects 0.000 claims description 6
- 210000003289 regulatory T cell Anatomy 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 238000002600 positron emission tomography Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 12
- 238000001514 detection method Methods 0.000 claims 2
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000032823 cell division Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1622214.3 | 2016-12-23 | ||
| GBGB1622214.3A GB201622214D0 (en) | 2016-12-23 | 2016-12-23 | treatment of cancer |
| GB1702565.1 | 2017-02-17 | ||
| GBGB1702565.1A GB201702565D0 (en) | 2017-02-17 | 2017-02-17 | Treatment of cancer |
| PCT/EP2017/084421 WO2018115458A1 (en) | 2016-12-23 | 2017-12-22 | Treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020501589A JP2020501589A (ja) | 2020-01-23 |
| JP2020501589A5 true JP2020501589A5 (enExample) | 2021-02-12 |
Family
ID=61189397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019534134A Pending JP2020501589A (ja) | 2016-12-23 | 2017-12-22 | がんの治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20200000861A1 (enExample) |
| EP (1) | EP3558377A1 (enExample) |
| JP (1) | JP2020501589A (enExample) |
| CN (1) | CN110869052A (enExample) |
| CA (1) | CA3047508A1 (enExample) |
| WO (1) | WO2018115458A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018170133A1 (en) * | 2017-03-15 | 2018-09-20 | Amgen Inc. | Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer |
| MX2019012741A (es) | 2017-04-28 | 2020-01-21 | Merck Sharp & Dohme | Biomarcadores para agentes terapeuticos contra el cancer. |
| TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
| US20230023987A1 (en) * | 2019-12-20 | 2023-01-26 | Board Of Regents, The University Of Texas System | Methods for treating cancer comprising low dose radiation |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9102126D0 (en) | 1991-01-31 | 1991-03-13 | Smithkline Beecham Biolog | Novel vaccine |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| EP1456652A4 (en) | 2001-11-13 | 2005-11-02 | Dana Farber Cancer Inst Inc | IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| JP2007511216A (ja) | 2003-11-17 | 2007-05-10 | クルセイド ラボラトリーズ リミテッド | 変異ウイルス |
| GB0326798D0 (en) | 2003-11-17 | 2003-12-24 | Crusade Lab Ltd | Methods for generating mutant virus |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| EP3153526B1 (en) * | 2008-01-31 | 2020-09-23 | INSERM - Institut National de la Santé et de la Recherche Médicale | Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2009148488A2 (en) * | 2008-05-29 | 2009-12-10 | The General Hospital Corporation | Use of oncolytic herpes viruses for killing cancer stem cells |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
| CN103079644B (zh) | 2010-06-11 | 2017-02-15 | 协和发酵麒麟株式会社 | 抗tim‑3抗体 |
| US9163087B2 (en) | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| WO2012135408A1 (en) | 2011-03-31 | 2012-10-04 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
| WO2013169739A1 (en) * | 2012-05-07 | 2013-11-14 | The General Hospital Corporation | Novel compositions and uses of anti-hypertension agents for cancer therapy |
| US9862932B2 (en) * | 2012-07-24 | 2018-01-09 | The General Hospital Corporation | Oncolytic virus therapy for resistant tumors |
| EP2879707A4 (en) * | 2012-08-01 | 2016-05-11 | Tetralogic Pharm Corp | Combination therapy |
| CN122399016A (zh) * | 2014-03-15 | 2026-07-17 | 诺华股份有限公司 | 使用嵌合抗原受体治疗癌症 |
| GB201408297D0 (en) * | 2014-05-12 | 2014-06-25 | Virttu Biolog Ltd | Treatment of cancer |
| EP3217993A1 (en) * | 2015-07-20 | 2017-09-20 | Virttu Biologics Limited | Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood |
-
2017
- 2017-12-22 JP JP2019534134A patent/JP2020501589A/ja active Pending
- 2017-12-22 EP EP17840533.8A patent/EP3558377A1/en not_active Withdrawn
- 2017-12-22 CA CA3047508A patent/CA3047508A1/en not_active Abandoned
- 2017-12-22 WO PCT/EP2017/084421 patent/WO2018115458A1/en not_active Ceased
- 2017-12-22 CN CN201780078679.8A patent/CN110869052A/zh active Pending
-
2019
- 2019-06-20 US US16/447,760 patent/US20200000861A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Simpson et al. | Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances | |
| JP2019065028A5 (enExample) | ||
| JP2022505022A5 (enExample) | ||
| Leung et al. | Bone marrow-derived alternatively activated macrophages reduce colitis without promoting fibrosis: participation of IL-10 | |
| FI3728313T3 (fi) | Syövän yhdistelmähoito IAP-antagonistilla ja anti-PD-1-molekyylillä | |
| WO2014172376A3 (en) | Markers of tumor cell response to anti-cancer therapy | |
| JP2018184465A5 (enExample) | ||
| Forbes et al. | Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses | |
| Belin et al. | An oncolytic vaccinia virus expressing the human sodium iodine symporter prolongs survival and facilitates SPECT/CT imaging in an orthotopic model of malignant pleural mesothelioma | |
| JP2016527202A5 (enExample) | ||
| Cuddington et al. | Oncolytic bovine herpesvirus type 1 as a broad spectrum cancer therapeutic | |
| JP2019526559A5 (enExample) | ||
| Jacobsen et al. | Effects of CCN1 and macrophage content on glioma virotherapy: A mathematical model | |
| White et al. | The histone deacetylase inhibitor valproic acid enhances equine herpesvirus type 1 (EHV-1)-mediated oncolysis of human glioma cells | |
| JP2017515847A5 (enExample) | ||
| Ghosh et al. | Exploring the potential of oncolytic viral vectors in targeted cancer therapy: advances, challenges and future directions | |
| Nishimura et al. | Fulminant myocarditis for non-small-cell carcinoma of the lung with nivolumab and ipilimumab plus chemotherapy | |
| Dave et al. | Viral warfare! Front-line defence and arming the immune system against cancer using oncolytic vaccinia and other viruses | |
| JP2009538935A5 (enExample) | ||
| Wittych et al. | Angiosarcoma of the scalp: a case report | |
| Guo | The impact of hypoxia on oncolytic virotherapy | |
| KR102780534B1 (ko) | 종양 진행 제어용 또는 항 종양 면역 회복용 대식 세포 및 조사된 백혈구의 공동 배양으로부터의 상청액 | |
| Pham et al. | Oncolytic viruses to augment PD-1 inhibition in metastatic cutaneous squamous cell carcinoma | |
| Zheltukhin et al. | Persistent virus presence during experimental oncolytic virus therapy in the model of subcutaneous mouse xenografts of human glyobolastoma multiforme | |
| Wong et al. | EXTH-61. Celecoxib improves OUTCOME of patients treated with tumor treating fields |